Evotec SE (EVO) Other Non-Current Assets (2009 - 2026)
Evotec SE (EVO) posted Other Non-Current Assets of $489.37 for Q1 2026, down 17.08% sequentially from $590.17 in Q4 2025, and down 84.24% YoY from $3105.2 in Q1 2025.
Evotec SE (EVO) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Evotec SE has reported Other Non-Current Assets for 9 years, with the latest figure at $489.37 in Q1 2026.
- Quarterly Other Non-Current Assets fell 84.24% year-over-year to $489.37 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $489.37 (down 84.24% YoY) and the FY2025 annual result came in at $590.17, down 99.98% from the prior year.
- Other Non-Current Assets retreated to $489.37 in Q1 2026 per EVO's latest filing, from $590.17 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $3.9 million in Q4 2022 and troughed at $489.37 in Q1 2026.
- A 5-year average of $706938.8 and a median of $2122.5 in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets soared 488.42% in 2022, then plunged 99.98% in 2025.
- Over 5 years, Other Non-Current Assets stood at $3.9 million in 2022, then plunged by 76.68% to $900561.7 in 2023, then soared by 311.03% to $3.7 million in 2024, then slumped by 99.98% to $590.17 in 2025, then declined by 17.08% to $489.37 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $489.37, $590.17, and $889.65 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Evotec SE | 692.56 Mn | 692.08 Mn | - | 489.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 489.37 |
| Dec 31, 2025 | 590.17 |
| Sep 30, 2025 | 889.65 |
| Jun 30, 2025 | 1,139.88 |
| Mar 31, 2025 | 3,105.16 |
| Dec 31, 2024 | 3.70 Mn |
| Mar 31, 2024 | 924.49 |
| Dec 31, 2023 | 900,561.70 |
| Dec 31, 2022 | 3.86 Mn |
| Sep 30, 2022 | 5,891.35 |
| Jun 30, 2022 | 5,453.73 |
| Mar 31, 2022 | 969.70 |
| Dec 31, 2021 | 5.89 Mn |
| Sep 30, 2021 | 1,001.21 |
| Dec 31, 2020 | 26,230.38 |
| Sep 30, 2010 | 3,977.12 |
| Jun 30, 2010 | 3,937.97 |
| Mar 31, 2010 | 5.04 |
| Dec 31, 2009 | 5,415.18 |
| Jun 30, 2009 | 2.13 Mn |